Taking the last decade, approximately 1,400 regular articles and clinical trials have been published evaluating the involvement of PPARγ on cancer development and its modulation or even anti-cancer profile of PPARγ agonists (data extracted from PUBMED on 24th July using the terms “PPARγ and cancer”). The gene discussed is PPARG; the disease is cancer.